FIRST AIRED: September 20, 2016

Nice work! Enjoy the show!


You’re busy. We get it.

Stay on top of the news with our Editor’s Picks newsletter.

US Edition
Intl. Edition
Unsubscribe at any time. One click, it’s gone.

Thanks for signing up!



>> It's a pharmaceutical giant with mountainous market value, and it's only ever been run by men, until now. Emma Walmsley is GlaxoSmithKline's new CEO, an insider with years of experience and an acute awareness of gender and equality in business.>> I very much take my responsibility seriously, alongside other female leaders, be it in business or in politics and how wonderful that we've made so much progress there recently.
But or also in academia, we all have a responsibility to be role models to inspire our daughters to stay ambitious.>> The role makes her the most powerful woman on the FTSE 100. GSK is worth twice as much as any other female led firm. It also brings the total number of women running those companies to seven.
Walmsley replaces retiring CEO, Andrew Witty, whose reputation suffered after the company was involved in a corruption scandal in China, leading to millions of pounds in fines. More recently, he was under pressure to increase profit, a task Walmsley appears well placed to achieve. She says she's extremely competitive. But shares fell after her appointment, many investors had favored an outsider.